DeepMed Research

University of Oxford

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Private

Established: 1096-01-01

Employees: 10K

Market Cap: -

Website: http://www.ox.ac.uk

Clinical Trials

A Comparative Study of Artekin With Standard Malarial Treatment Regimes in Afghanistan

Phase 3

Completed

Conditions: Uncomplicated Falciparum Malaria
Vivax Malaria

Interventions: Drug: artesunate-sulphadoxin/pyrimethamine, chloroquine
Drug: Dihydroartemisinin + Piperaquine (Artekin)

First Posted Date: 2008-05-22

Last Posted Date: 2018-05-09

Lead Sponsor: University of Oxford

Target Recruit Count: 1086

Registration Number: NCT00682578

Locations: 🇦🇫
Provincial Malaria Control Centers (MRC), Takhar, Afghanistan

A Study of MVA85A in Healthy Children and Infants

Phase 2

Completed

Conditions: Tuberculosis

Interventions: Biological: MVA85A
Biological: Prevenar

First Posted Date: 2008-05-16

Last Posted Date: 2010-02-09

Lead Sponsor: University of Oxford

Target Recruit Count: 168

Registration Number: NCT00679159

Locations: 🇿🇦
University Cape Town, Worcester, Western Cape, South Africa

A Phase I Study to Assess the Safety and Immunogenicity of Tuberculosis (TB) Vaccine Candidates FP85A and MVA85A

Phase 1

Completed

Conditions: Tuberculosis

Interventions: Biological: FP85A
Biological: MVA85A

First Posted Date: 2008-04-07

Last Posted Date: 2010-02-09

Lead Sponsor: University of Oxford

Target Recruit Count: 31

Registration Number: NCT00653770

Locations: 🇬🇧
CCVTM, University of Oxford, Oxford, United Kingdom

Study of the Safety and Immunogenicity of Bacille Calmette Guerin (BCG) Vaccine

Phase 1

Completed

Conditions: TB

Interventions: Biological: BCG

First Posted Date: 2008-04-07

Last Posted Date: 2008-04-07

Lead Sponsor: University of Oxford

Target Recruit Count: 11

Registration Number: NCT00654316

Locations: 🇬🇧
Centre for Clinical Vaccinology and Tropical Medicine, Oxford, Oxfordshire, United Kingdom

A Study to Quantify Bacille Calmette Guerin (BCG) and Characterise the Immune Response After BCG Vaccination

Phase 1

Completed

Conditions: Tuberculosis

Interventions: Biological: BCG

First Posted Date: 2008-04-07

Last Posted Date: 2010-07-01

Lead Sponsor: University of Oxford

Target Recruit Count: 40

Registration Number: NCT00653627

Locations: 🇬🇧
CCVTM, University of Oxford, Oxford, United Kingdom

A Randomised Controlled Trial of Iodide Supplementation in Preterm Infants Follow-up at 2 Years

Phase 4

Completed

Conditions: Transient Hypothyroxinemia

Interventions: Drug: Sodium Chloride
Drug: sodium iodide

First Posted Date: 2008-03-18

Last Posted Date: 2015-05-18

Lead Sponsor: University of Oxford

Target Recruit Count: 1275

Registration Number: NCT00638092

Locations: 🇬🇧
Ninewells Hospital and Medical School, Dundee, Tayside, United Kingdom
🇬🇧
Royal Maternity Hospital, Belfast, United Kingdom
🇬🇧
Heartlands Hospital, Birmingham, United Kingdom

and more 16 locations

A Randomized Double Blinded Comparison of Ceftazidime and Meropenem in Severe Melioidosis

Not Applicable

Conditions: Melioidosis

Interventions: Drug: Meropenem
Drug: Ceftazidime

First Posted Date: 2007-12-24

Last Posted Date: 2008-06-04

Lead Sponsor: University of Oxford

Target Recruit Count: 750

Registration Number: NCT00579956

Locations: 🇹🇭
Sappasithiprasong Hospital, Ubonratchathani, Ubon, Thailand
🇹🇭
Udon Thani General Hospital, Udon Thani, Thailand

T-Cell Turnover Following Vaccination With MVA85A

Phase 1

Completed

Conditions: Tuberculosis

Interventions: Biological: MVA85A
Other: Deuterated glucose infusion

First Posted Date: 2007-10-24

Last Posted Date: 2010-01-18

Lead Sponsor: University of Oxford

Target Recruit Count: 12

Registration Number: NCT00548444

Locations: 🇬🇧
University of Oxford, Oxford, Oxfordshire, United Kingdom

Clinical Investigation of In-vivo Susceptibility of P.Falciparum to Artesunate in Western Cambodia

Not Applicable

Completed

Conditions: Falciparum Malaria

Interventions: Drug: Artesunate + Mefloquine
Drug: Artesunate

First Posted Date: 2007-06-28

Last Posted Date: 2018-05-04

Lead Sponsor: University of Oxford

Target Recruit Count: 40

Registration Number: NCT00493363

Locations: 🇰🇭
Pailin Referal Hospital, Pailin, Cambodia

Safety, Immunogenicity, and Impact of MVA85A, on the Immunogenicity of the EPI Vaccines

Phase 1

Completed

Conditions: TB

Interventions: Biological: MVA 85A

First Posted Date: 2007-05-31

Last Posted Date: 2010-02-09

Lead Sponsor: University of Oxford

Target Recruit Count: 214

Registration Number: NCT00480454

Locations: 🇬🇲
MRC, Banjul, Gambia

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy